Investment analysts at StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the specialty ...
Research analysts at HC Wainwright issued their FY2025 EPS estimates for Grace Therapeutics in a research note issued to investors on Tuesday, February 18th. HC Wainwright analyst O. Livnat ...
H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Biotricity (BTCY – Research Report) today. The company’s shares closed yesterday ...
On Tuesday, H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics Inc (NASDAQ:TNYA), with a price target of $18.00. This aligns with the strong overall analyst ...
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (BRSE:1CG) with a Buy recommendation. There are 575 funds or institutions reporting positions ...
On January 31, the company announced that H.C. Wainwright & Co. has initiated coverage on it with a “Buy” rating and a 12-month price target of $16 per share. The report highlights several ...
--(BUSINESS WIRE)--Knightscope, Inc. (NASDAQ: KSCP), an innovator in robotics and artificial intelligence technologies focused on public safety, today announced that H.C. Wainwright & Co. has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results